Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
Lucie Raskin, PhD student at University of Namur, shared on LinkedIn:
”Glad to have presented at NTHC 2026 (Namur Thrombosis and Hemostasis Center)!
I had the opportunity to share our work on a Network Meta-Analysis (NMA) assessing the risk of venous thromboembolism (VTE) associated with hormonal contraceptives (HCs).
This analysis allows us, within a single model, to compare the full range of HCs and to classify VTE risk according to the type of contraceptive.
By integrating all available evidence, this work provides a comprehensive overview that complements biological data and real-world pharmacovigilance findings.
Altogether, the evidence consistently suggests that natural estrogens may represent a safer option compared to EE-based COCs with respect to VTE risk.
I would like to thank my supervisors Jonathan Douxfils and Charlotte Beaudart, as well as the Research Unit in Clinical Pharmacology and Toxicology (URPC) team for their support.”
Stay updated with Hemostasis Today.
-
Aug 28, 2026, 15:10Ify Osunkwo: Strengthening Sickle Cell Care Systems at Global Conference in Nairobi
-
Aug 28, 2026, 15:08Muhammed Safvan: One Drop of Blood Can Tell a Story
-
Aug 28, 2026, 14:52Jessica Lee: Standing Together for Children and Families with Bleeding Disorders
-
Aug 28, 2026, 14:45Daisy Souster: A New Chapter in Bleeding Disorder Advocacy
-
Aug 28, 2026, 14:42Oluwatoyin Iyabode Ajayi: Heavy Periods – When Is Menstrual Bleeding Too Much?
-
Aug 28, 2026, 14:20Alyson Reidy: Factor Man and Community Support Take Center Stage at NBDF 2026
-
Aug 28, 2026, 14:09New Study Highlights Pregnancy Challenges in Inherited Bleeding Disorders – Glanzmann’s Research Foundation
-
Aug 28, 2026, 13:55Swatee C: A Guide to Common Uterine Disorders
-
Aug 28, 2026, 12:14Gathoni Kungu: Run to End Postpartum Hemorrhage and Save Lives